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ABSTRACT
G protein-coupled receptors are the most abundant
mediators of both human signalling processes and
therapeutic effects. Herein, we report GPCRome-
wide homology models of unprecedented quality,
and roughly 150 000 GPCR ligands with data on bio-
logical activities and commercial availability. Based
on the strategy of ’Less model – more Xtal’, each
model exploits both a main template and alternative
local templates. This achieved higher similarity to
new structures than any of the existing resources,
and refined crystal structures with missing or dis-
torted regions. Models are provided for inactive, in-
termediate and active states––except for classes C
and F that so far only have inactive templates. The
ligand database has separate browsers for: (i) tar-
get selection by receptor, family or class, (ii) ligand
filtering based on cross-experiment activities (min,
max and mean) or chemical properties, (iii) ligand
source data and (iv) commercial availability. SMILES
structures and activity spreadsheets can be down-
loaded for further processing. Furthermore, three re-
cent landmark publications on GPCR drugs, G pro-
tein selectivity and genetic variants have been ac-
companied with resources that now let readers view
and analyse the findings themselves in GPCRdb. Al-
together, this update will enable scientific investiga-
tion for the wider GPCR community. GPCRdb is avail-
able at http://www.gpcrdb.org.
INTRODUCTION
G protein-coupled receptors represent both the largest
membrane and drug target protein families, accounting for
800 (4%) human genes and 34% of FDA-approved drug
targets (1). The human GPCRs have been divided into six
classes (or families): A (Rhodopsin), B1 (Secretin), B2 (Ad-
hesion), C (Glutamate), F (Frizzled) and Taste 2 based on
evolutionary homology (2,3). All GPCRs share a common
heptahelical transmembrane domain carrying the signal
from the extracellular ligand to the intracellular signalling
protein, typically one of four families of G proteins or -
arrestin, which can also internalise the receptor. Recently,
structural biology and pharmacology breakthroughs have
opened up new GPCR research fields exploring structural
mechanisms and complexes, and novel principles to achieve
a more selective action through ’biased agonism’ preferen-
tially activating a specific signal protein or ’allosteric mod-
ulation’ of the natural ligand response from an alternative
binding site. TheGPCRdatabase,GPCRdb (4–6) serves the
wide GPCR community, currently ∼1800 monthly users,
with reference data, web server analysis tools and dynamic
visualisation of data and statistics. Current data ranges all
398 human non-olfactory GPCRs and 16 G proteins, over
14 000 species orthologues, 30 328 binding site mutations,
all 218 experimental structures, and 10 059 extracted ligand
interactions.
GPCR crystal structures have now been determined for
the major human classes A–C, F (D and E fungal and
amoeba receptors, respectively), but not yet for the Adhe-
sion (B1) and Taste 2 classes, which have atypical pharma-
cology in that they are not activated by an endogenous ag-
onist. In total, structures are available for 46 unique recep-
tors, however close to 90% of the non-olfactory receptors
still lack a crystal structure (http://gpcrdb.org/structure/
statistics). Furthermore, only eleven receptors have a struc-
ture in the active state. Hence, many GPCR studies utilise
homology models for virtual screening, lead optimisation,
elucidation of ligand binding sites, off-target rationalisa-
tion, modeling of complexes, and molecular dynamics (7).
The latest GPCR Dock assessment (8) showed that the ac-
curacy of such models has greatly increased, and the best
models utilize more than one template. Our 5-HT1B model
achieved the best RMSD compared to the crystal structure
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and was based on five backbone templates and a position-
specific rotamer library derived from all GPCR structures.
This strategy of ’Less model––more Xtal’ covers more of
the model with experimental data by extending the main
template with alternative local templates for missing or dis-
torted segments. Herein, we present the first resource with
pre-generated multi-template models of all human non-
olfactory GPCRs in their inactive, intermediate and active
states (except for classes C and F for which active and inter-
mediate templates are still missing).
GPCR ligands have previously been collated in a dedi-
cated resource, GLIDA database (9), but maintenance was
discontinued in October 2010 when the database contained
30,399 ligands. Today, the Guide to PHARMACOLOGY
database offers curated reference ligands for a large num-
ber of protein families, including GPCRs (10), however this
is just a small subset of the publically available ligands. The
most comprehensive resource for biological activities is the
ChEMBL database, which has compiled data from pub-
lications, patents and commercial sources (11). However,
ChEMBLdata is not presented and filtered to be directly ac-
cessible bymany users. A further resource is theKi database
of the psychoactive drug screening programme containing
broad target profiling, however most of which are single-
point values (12). Herein, we present a new GPCR lig-
and resource that applies the same quality requirements as
Guide to PHARMACOLOGY, but encompasses ligands
fromChEMBL,GLIDAand the PDSPKi database. It gives
users novel possibilities, such as commercial availability, tar-
get selectivity and selection of ligands suitable for crystal-
lography experiments.
METHODS
Technical features of the homology modeling pipeline
The new GPCRdb homology modeling pipeline (Figure 1)
updates the templates and models upon each database up-
date. It was developed in Python in the Django web frame-
work, utilizes several tools from Biopython (13), saves data
in a PostgreSQL database, builds the final models with
the help of MODELLER 9.18 (14) and uses NGL (15)
for model visualisation. It leverages on integration of sev-
eral unique manually annotated GPCRdb resources, in-
cluding structure-based sequence alignments with generic
residue numbers (16), GPCR structures (all in PDB) with
defined preferred chain, helix segment borders, and dis-
torted regions; and a position-specific sidechain rotamer li-
brary (17).
Pairwise sequence alignment
Target-template pairwise sequence alignments are fetched
from GPCRdb.
Main template selection
For each receptor with a structure at least one (the most
complete) representative template (currently totalling 169)
has been manually annotated to define aligned segments
(TM1–7, H8, ICL1–2 and ECL1–2), bulges, constrictions
1. Class 
2. State 
3. Sequence similarity 
4. Structure coverage 
5. Resolution 
Main template selection 
Helix end adjustment 
Loop swap-in 
Helix bulge/constriction 
Sequence Alignment Sidechain rotamers 
Disulphide bridges 
Steric clash removal 
Non-template modelling 
Figure 1. The GPCRdb homology model pipeline builds on the principle
of ’Less model – more Xtal’ meaning that more of the target is covered by
structural templates, as an incomplete or partly distorted main template is
complemented with alternative local templates. All templates and models
are automatically updated upon each database update. Models are pro-
duced for all the human non-olfactory GPCRs in the inactive, and where
templates exist (classes A and B1), also intermediate and active states.
and any missing or distorted regions. A model main tem-
plate is selected based on: (i) class (B2 to B1 and Taste2
to A), (ii) state (active/intermediate/inactive), (iii) recep-
tor sequence similarity, (iv) structure coverage (no. generic
residue positions (16) with coordinates) and (v) resolution.
The template states are defined based on the extend of out-
ward and inward movement of TM6 and TM5, respec-
tively, on the intracellular, G protein binding side (http:
//docs.gpcrdb.org/structures.html#structure-state).
Helix end adjustment
Transmembrane helix ends are in some places (typically in
ICL3) altered due to protein fusions, H8 is sometimes miss-
ing or truncated, and both can be distorted due to crys-
tal packing effects. Non-native parts of helices are removed
from the initial model and missing segments are modeled
Downloaded from https://academic.oup.com/nar/advance-article-abstract/doi/10.1093/nar/gkx1109/4634004
by Kobenhavns Universitets user
on 18 December 2017
Nucleic Acids Research, 2017 3
based on a local alternative template, which is superposed
onto the last helical turn of the main template.
Loop modeling
As a unique feature, GPCRdb has alignments and generic
residue numbers for loop regions with a conserved sec-
ondary structure; ECL1: three-residue turn motif with ter-
minal amino acids packing between TM2-TM3, ICL1:
single-turn helix, ECL2: cysteine forming a disulphide
bridge to TM3 plus two following residues, and ICL2: two-
turn helix. This allows our pipeline to model these loops
based on alternative templates, where needed. Structurally
disordered loops are also modeled based on an alternative
template if themain template is incomplete, distorted or has
a different length than the target. An alternative template
is chosen based on length (as many residues as the target),
sequence similarity, structure coverage and resolution. The
template is superposed on the adjacent helix ends, except
for ECL2 for which a first and latter half are anchored on
the backbone of the conserved cysteine (position 45x50). If
the main template structure lacks the backbone coordinates
of the conserved ECL2 cysteine, these are inferred from an
alternative template that is superposed using the last TM4
residue, first TM5 residue and the conserved cysteine in
TM3 (3x25) that makes up the other half of the disulphide
bridge. Altogether, this ensures that only a few remaining
loop stretches need to be modeled without a template.
Helix bulge and constriction treatment
When the target or template has a unique 7TM helix bulge
or constriction (a local turn of - or 310-helix, respectively),
a swap-in template with the same configuration as the tar-
get is applied. Such helix distortions are associated with
characteristic sequence motifs, typically involving proline
or glycine residues, and have been uniquely accounted in
the GPCRdb alignments and residue numbers (16).
Sidechain rotamer modeling
Amino acids not conserved between the target and
main template are defined from a position-specific ro-
tamer library extracted from all experimental GPCR
structures (17). A conserved amino acid from the same
structure/sequence position is superposed onto the back-
bone atoms of the original residue. In practice, this gen-
erates a chimeric structural template with a significantly
higher sequence identity, often over 20%, to the target than
a single template. Also, template mutations, introduced to
facilitate expression and crystallization, are reverted to the
wildtype residue using the rotamer library.
Disulphide bridge introduction
Two conserved disulphide bridges are modeled: (i) one
cross-class between the top of TM3 (3x25) and ECL2
(45x50) and (ii) another present in some class A receptors
that links two cysteines in ECL3 or ECL3 to the top of
TM6.
Non-template-based modeling of remainder
Residues not covered by a structural template get their
missing backbone and/or sidechains modeled using
MODELLER (14), which also re-models non-conserved
sidechains with a steric clash.
Building of a GPCR ligand database with information about
commercial availability
Ligands and biological activities were imported from
ChEMBL 23 using the ChEMBL protein IDs and
API (11). Records were filtered to only include the
standardised/translated pChEMBL values and the binding
and functional assay types, while excluding those with
disqualifying statuses in ‘data validity comment’ and
‘activity comment’ (see https://www.ebi.ac.uk/chembl/faq).
Ligand chemical (molecular weight, no. hydrogen bond
donors/acceptors and rotatable bonds) and commercial
availability data (vendor and catalogue number) were
retrieved from PubChem (18) after building a translation
routine between ChEMBL and PubChem compound
identifiers.
RESULTS
Recent resources for GPCR drugs, G protein coupling selec-
tivity and natural genetic variants
Three recent high-impact publications have been accompa-
nied with tailored resources that integrate biologically and
clinically relevant data and let researchers make their own
analyses online at GPCRdb. The first new section, ‘Drugs’,
supplement an analysis of the new trends for GPCR drugs,
targets and indications covering FDA-approved drugs and
agents in clinical trials (1). The first item is Drug statistics
concerning, e.g. targets, drug molecule types and modes of
action, disease indications and clinical phase distributions.
Secondly, a Drug target mapping page shows the distribu-
tion of in-trial and approved clinical agents onto a target
tree classification of GPCR classes, ligand types and recep-
tor families to give a rapid overview for targets of interest.
Finally, a Drug browser allows for navigation and filtering
of complete information for drugs, targets, indications, clin-
ical progression and references.
The second new section, ‘Signal Proteins’, was added as
part of a landmark study on GPCR-G protein selectivity
(19). This features selection of human receptor sets by their
GPCR-protein coupling data, G protein sequence align-
ments and residue topology diagrams, structures, interface
mapping and search and in vitro mutations of GPCRs
and G proteins with effect on signalling. The third new
(sub)section Genetic variation (found in the Receptors sec-
tion) was added as part of a comprehensive report on phar-
macogenomics of GPCR drug targets (20). This subsec-
tion features Variation statistics with counts and densities
of missense and loss of function polymorphisms across re-
ceptors, receptor families, ligand types andGPCR classes; a
Receptor variant browser tabulating missense variant data
and functional annotations (such as ligand and effector
protein binding sites, post-translational modification sites,
sodium ion pocket and micro-switches) by target(s) and
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Figure 2. RMSD (A˚) values of database/server homology models calcu-
lated directly upon release of the first structure for four GPCRs (AA1R:
mapping their topology in receptor residue diagrams; as
well as an Estimated economic burden caused by genetic
variation along with UKNHS sales and prescription infor-
mation per drug.
Ready-to-usemodels of several states for all non-olfactory hu-
man GPCRs
GPCRdb contains inactive state models of all human non-
olfactory GPCRs and intermediate as well as active state
models for classes (families) A (Rhodopsin), B1 (Secretin),
B2 (Adhesion) and T (Taste 2). This includes also refined
experimental structures filling in missing and replacing dis-
torted regions and reverting mutated amino acids (added
to the Structure Browser). Models are listed on the recep-
tor pages, but also available from a new homology model
browser (http://gpcrdb.org/structure/homology models) al-
lowing for multiple structures to be filtered, superposed, as-
signed generic residue numbers and downloaded. Finally,
each receptor model has a page with embedded visualisa-
tion and details of which templates were utilised for which
segment.
Homology model accuracy
Figure 2 showsRMSD values of database/server homology
models calculated directly upon release of the first struc-
ture for four GPCRs. The GPCRdb homology models have
the best average RMSD values in all four categories: overall
(2.8 A˚), 7TM (2.3 A˚), ligand site (1.8 A˚) and ECL2 (3.7 A˚).
Among other databases with pre-generated models (blue
background), GPCR-I-TASSER performs the best, espe-
cially in the overall and 7TM. In contrast, three modeling
web servers (gray background) perform best in different cat-
egories; SWISS-MODEL: overall, GPCRM: 7TM and lig-
and site, andGPCR-ModSim: ECL2.As could be expected,
the RMSDs of the overall and 7TM models correlate di-
rectly with the sequence similarities and identities to the
main template (bottom of figure). Altogether, the compar-
isons confirm the technological advantages of the GPCRdb
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
5UEN, CCR2: 5T1A, PAR2: 5NDD and APJ: 5VBL). Notably, the
GPCRdb homology models have the best average RMSD values in all four
categories. Superimposition was performed on backbone heavy atoms.
For comparability, RMSD calculations were restricted to residues present
in all of the models. SWISS-MODEL settings: default, used main tem-
plate listed on top. GOMoDo settings: Blast – 2 search rounds, MOD-
ELLER options––twomodels, global alignment (no realign templates), no
loop refinement, chose model with best normalized DOPE score (PAR2
model was sixth best, ones before were incomparable due to a shift in se-
quence numbering). GPCRM settings (kindly provided by the developers):
beta version (under development), ECL2 disulphide bridge specified, Task
mode Auto, Set of templates inactive, Lysozyme do not add from template,
Rosetta loop-modeling yes, fast, additional options left default. Selected
r01 model. GPCR-ModSim settings (kindly provided by the developers):
group inactive, alignment was edited, number of models 10, selected one
with best DOPE score, no Lenard-Jones restraints, select top templates –
default, ECL2 disulphide bridge specified, short loops ICL1, ECL1, ICL2
andECL3weremodeled with loopmodeling, number ofmodels 5, selected
one with best DOPE score, no MD. GPCR-i-TASSER model selection
from repository: Model 1. GPCR-SSFE model selection from repository:
EntireModel1, loop versions 0.
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Example model: Inactive state GPR75 
Based on 10 backbone and 27 rotamer templates 
Segment Start 
pos 
End 
pos 
Backbone 
Template 
TM1 35 38 3P0G 
TM1 39 70 4U15 
ICL1 71 72 None 
ICL1 73 76 4U15 
TM2 77 107 4U15 
ECL1 108 108 None 
ECL1 109 109 4PXZ 
ECL1 110 110 None 
TM3 111 113 4PXZ 
TM3 114 149 4U15 
ICL2 150 150 None 
ICL2 151 155 5DYS 
ICL2 156 156 None 
TM4 157 183 4U15 
ECL2 184 188 None 
ECL2 189 191 4U15 
ECL2 192 192  None 
ECL2 193 197 3VW7 
ECL2 198 198 None 
TM5 199 199 4XT1 
TM5 200 209 4U15 
TM5 210 211 3V2Y 
TM5 212 231 4U15 
TM5 232 240 3SN6 
ICL3 241 245 None 
ICL3 305 309 None 
TM6 310 313 5TVN 
TM6 314 347 4U15 
ECL3 348 348 None 
ECL3 349 352 2YDV 
ECL3 353 353 None 
TM7 354 379 4U15 
H8 380 391 4U15 
H8 392 392 3SN6 
Figure 3. Example model of the inactive state GPR75. The colors indi-
cate the use of 10 different backbone template to fill in lacking coordi-
nates, elongate helices, add missing secondary structure segments to loops
and to remove a main template helix bulge not shared by GPR75. Further-
more, the use of 27 sidechain templates from the GPCR position-specific
rotamer library increased the percentage of residues that could be based
on an identical amino acid from 15.7% to 58.2%.
homology modeling pipeline, which gives all researchers ac-
cess to ready high-quality models without the need for own
configuration.
Example model
Figure 3 shows an example model, the inactive state
GPR75, which was based on 10 backbone and 27 sidechain
templates. Alternative backbone templates were used to
extend helices that were too short in the main template.
These were TM1 start (3P0G), TM3 start (4PXZ), TM5
start (4XT1), TM5 end (3SN6), TM6 start (5TVN) and H8
end (3SN6). This feature is especially useful in the TM5-
ICL3-TM6 region, where most GPCR crystal structures
have non-native conformations due to fusion proteins. Al-
ternative templates were also used for loops that differed
in length or had missing coordinates. These were ECL1
(4PXZ), ICL2 (5DYS), ECL2 (3VW7) and ECL3 (2YDV).
In TM5, an alternative template was used to remodel amain
template bulge not present in the GPR75 alignment, as this
does not share the associated sequencemotif. Finally, by ap-
plying our GPCR position-specific rotamer library, the per-
centage of residues that could be modeled from an identical
amino acid increased from 15.7% to 58.2%.
The GPCRdb ligand database and statistics
This first instalment of the GPCRdb ligand database con-
tains 144 773 ligands, 597 targets, 29,530 assay experiments
amounting to ∼320 000 activity records. A dedicated lig-
and statistics page has been added to provide continuously
updated distributions of ligands across the GPCR classes.
Overall statistics is provided in a table listing the numbers
of: ligands, average ligands per receptor and receptors that
have a ligand. Specific receptors and receptor families are
shown in trees, as also illustrated in Figure 4. The vast ma-
jority of ligands (91%) are found for class A GPCRs with
great abundance (>1000 ligands) for aminergic, adenosine,
opioid receptors, but no or very few ligands for the many
understudied orphan receptors.
Ligand Browser
The ligand browser spans four separate pages for target se-
lection, ligand filtering, ligand source data and commercial
availability; all of which allow for filtering directly in the col-
umn headers. The first page allows for selection of targets on
the level of receptors, receptor families or classes, while dis-
playing the numbers of associated ligands. The second page
shows themin, max andmean activities for ligand-receptor-
species triads across all their experiments; hence provide a
non-redundant overview suitable for filtering of ligands by
their activities, commercial availability and chemical prop-
erties, such as logP. The negative logarithmic (p) values
are used to compare the large span of affinities/activities,
which are also provided in nanomolar units. A third page
allows users to retrieve the exact ligand activities in all sep-
arate assay experiments. The fourth and final page adds
vendor names and identifiers to facilitate ligand purchases.
The three ligand-containing pages have the option to down-
load ligands smiles (with ChEMBL identifies) and activity
spreadsheets (csv format) to facilitate further processing.
CONCLUSIONS AND OUTLOOK
In the last two years, GPCRdb has enabled and dissemi-
nated high-impact biological analyses (1,19,20), through re-
sources that also allow scientists to analyse the data them-
selves. Herein, we have reported homology models of un-
precedented quality for all human non-olfactory GPCRs
and across activity states. The models will stay up to date,
as the integrated pipeline incorporates new templates upon
database re-building. The structural completeness and pre-
cise rotamers of the GPCRdb homologymodels make them
uniquely suited for molecular dynamics and docking, re-
spectively. The GPCRdb ligand database allows users to
find relevant tool compounds and drugs faster and to know
where to buy them, thereby facilitating experimental stud-
ies across many GPCR disciplines. Going forward it would
be very valuable to expand from ChEMBL to additional
ligand sources and to implement a ligand selectivity filter.
Furthermore, the structural revolution within the GPCR
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Figure 4. Trees showing the human GPCR classes (GRAFS family): A (Rhodopsin), B1 (Secretin), B2 (Adhesion), C (Glutamate), F (Frizzled) and T:
Taste 2. Each tree is sorted alphabetically by ligand type (only class A) and receptor families which share the same physiological ligand. The tree branches
are color-coded by ligand types, and the gray-scale circles before receptor names indicate their number of ligands (white: 0, light gray: >100, gray: >500
and black: >1000).
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field should now allow for analysis of the successful con-
structs and data-driven design toward more structures. Fi-
nally, GPCR signalling is a hot topic warranting additional
resources, such as -arrestin data, GPCR-G protein com-
plex models and a database of published biased agonists.
AVAILABILITY
GPCRdb is available at http://www.gpcrdb.org and can also
be accessed via REST web services, as exemplified at http:
//docs.gpcrdb.org/web services.html. The open source code
and a virtual machine is available at https://github.com/
protwis/protwis.
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